BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Aglatimagene Besadenovec readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Aglatimagene Besadenovec\, from ClinicalT
 rials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07332000-2093@assetmemo.bio
DTSTAMP:20261121T011043Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Aglatimagene Besadenovec: Phase 2 readout est. (NCT07332000)
DESCRIPTION:Aglatimagene Besadenovec\, phase 2.\nStudy: A Biomarker Study i
 n Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
 \nEstimated primary completion: February 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/aglatimagene-besadenovec#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07332000
URL:https://assetmemo.bio/drug/aglatimagene-besadenovec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07660094-2093@assetmemo.bio
DTSTAMP:20261121T011043Z
DTSTART;VALUE=DATE:20311022
DTEND;VALUE=DATE:20311023
SUMMARY:Aglatimagene Besadenovec: Phase 3 readout est. (NCT07660094)
DESCRIPTION:Aglatimagene Besadenovec\, phase 3\, Non-Small Cell Lung Cancer
 .\nStudy: Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxe
 l for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)\nE
 stimated primary completion: 22 October 2031. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/aglatimagene-besadenovec#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07660094
URL:https://assetmemo.bio/drug/aglatimagene-besadenovec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
